Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
SYRE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.71 - $40.84
Previous CloseN/A
Volume84.75K
Average Volume (3M)632.50K
Market Cap
$1.08B
Enterprise Value$839.17M
Total Cash (Recent Filing)$89.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)2.3
Beta0.59
Next Earnings
May 08, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.16
Shares Outstanding60,257,023
10 Day Avg. Volume641,731
30 Day Avg. Volume632,497
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1340.21
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.02
Forecast
1Y Price Target
$56.60Price Target Upside215.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Spyre Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Combination TherapiesSPY003's potential Q3M/Q6M schedule could significantly reduce injection burden while delivering equivalent or possibly even higher therapeutic exposures.
Financial StabilitySpyre Therapeutics has more than 3.5 years of cash available, providing financial stability for future developments.
Preclinical DataSPY003's preclinical data looks encouraging, assuming the average YTE half-life extension of ~3x the NHP half-life.
Bears Say
Antibody RatesHigh anti-drug antibody (ADA) rates are common with anti-TL1A agents.
Clinical DataThere is a need to show competitive data on other parameters, such as remission or ADA rates, to move the needle.
Market TimingIf for whatever reason the combo dream falls apart, Spyre would be left only with a late-to-market TL1A + convenience story, which would not be sufficient to justify stock valuation.
---
Ownership Overview
9.67% Insiders
19.97% Mutual Funds
50.52% Other Institutional Investors
10.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $16.71 and its highest was $40.84 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $1.08B.
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 38 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.986 by $0.176.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -0.84.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 60,257,023 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.986. Following the earnings report the stock price went up 7.24%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Currently, no hedge funds are holding shares in SYRE
---
Spyre Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.60 (215.50% Upside)
$56.60 (215.50% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.70%
12-Months-Change
Fundamentals
Return on Equity
-42.90%
Trailing 12-Months
Asset Growth
77.99%
Trailing 12-Months
Company Description
Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
---
SYRE Stock 12 Month Forecast
Average Price Target
$56.60
▲(215.50% Upside)
Technical Analysis
Best Analysts Covering SYRE
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+34.48%
reiterated a buy rating 2 months ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +34.48% per trade.
---